High-throughput sequencing analysis of differential microRNA expression in the process of blocking the progression of chronic atrophic gastritis to gastric cancer by Xianglian Huazhuo formula
机构:[1]Department of spleen and stomach diseases, First Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang 050000, China.[2]Department of Traditional Chinese Medicine, Hebei General Hospital, Shijiazhuang 050051, China.[3]Department of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.深圳市中医院深圳医学信息中心[4]College of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050011, China.
To explore the mechanism of Xianglian Huazhuo formula (, XLHZ) blocking the development of chronic atrophic gastritis (CAG) to gastric cancer (GC) through bioinformatics analysis and in vitro.Pathological morphology of gastric mucosa of rats were observed. High-throughput sequencing was used to analyze the miRNA expression profile of gastric mucosa. The miRanda, miRDB and miRWalk databases were used to predict the differential target genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed for differential target genes. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to verify the differentially expressed miRNAs and target genes. Western blot, EdU, wound healing and flow cytometry were used to observe the effect of XLHZ on epithelial-mesenchymal transition (EMT) markers, proliferation, migration, apoptosis and cell cycle of CAG cells in vitro.A total of five differentially expressed miRNAs and four differential target genes were screened in this study. GO analysis showed that the target genes were enriched in regulation of neuron development, regulation of transcription factor activity and regulation of RNA polymerase. KEGG pathways database differences in gene enrichment of target genes in the Wnt signaling pathway, Phospholipase D signaling pathway and mitogen-activated protein kinase signaling pathway. qRT-PCR confirmed that miRNAs and its target genes were consistent with the screening results. In vitro, our study revealed that XLHZ could increase the expression of E-cadherin, decrease the expression of transforming growth factor β1, vimentin and β-catenin, inhibite the proliferation and migration of CAG cells, cause cell cycle arrest at G0/G1 and G2/M phase, induce the apoptosis of CAG cells, and prevent the progression of CAG to GC.This study provided a new idea for the mechanism of blocking the progression of CAG to GC by XLHZ, which may be related to the expression of miR-20a-3p, miR-320-3p, miR-34b-5p, miR-483-3p and miR-883-3p and their target genes transferrin receptor, nuclear receptor subfamily 4 member 2, delta like canonical Notch ligand 1 and a kinase anchor protein 12 in CAG. In the future, we will continue to investigate the linkage between the active ingredients of XLHZ and the relevant miRNAs and their target genes, so as to provide more sufficient experimental basis for clinically effective prevention of CAG to GC.
基金:
Construction Project of National Clinical Research Base
of Traditional Chinese Medicine (Science Letter [2018] No. 131, State
Office of Traditional Chinese Medicine); Natural Science Foundation
of Hebei Province: Study on the Mechanism of Action of Traditional
Chinese Medicine on Disease and Syndrome (No. H2023423001); Key
Research Project of the Ministry of Science and Technology (No.
2018YFC1704100); Key Research Project of the Ministry of Science
and Technology: Li Diangui Famous Old Chinese Medicine of
Traditional Chinese Medicine Academic View Characteristic,
Diagnosis and Treatment Methods and Experience of Prevention and
Control of Major Diseases (No. 2018YFC1704102); Provincial Science
and Technology Program of Hebei Province: Prevention and Treatment
of Gastric Cancer by Blocking the "Inflammation-Cancer
Transformation" Based on the Theory of Turbidimetric Toxicity (No.
21377724D); Provincial Science and Technology Program of Hebei
Province: to Study the Clinical Efficacy and Mechanism of Huazhuo
Jiedu Formula in the Treatment of Chronic Atrophic Gastritis based on
Epidermal Growth Factor Receptor/Mitogen Activated Protein
Kinase/Extracellular Signal-Regulated Kinase Signaling Pathway (No.
21377740D); Scientific Research Project of Hebei Administration of
Traditional Chinese Medicine: Clinical Study of Huazhuo Jiedu
Formula Blocking the Pathological Evolution of Chronic Atrophic
Gastritis (No. 2022026); Scientific Research Project of Hebei
Administration of Traditional Chinese Medicine: Study on the
Medication Rules of Spleen and Stomach Diseases of Famous Yanzhao
Medical Doctors Based on Data Mining (No. 2022032); Scientific
Research Project of Hebei Administration of Traditional Chinese
Medicine: to Explore the Mechanism of Xianglian Huazhuo Formula
in the Treatment of Chronic Atrophic Gastritis based on
Transcriptomics (No. 2023022)
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
无
最新[2025]版:
大类|4 区医学
小类|4 区全科医学与补充医学
第一作者:
第一作者机构:[1]Department of spleen and stomach diseases, First Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang 050000, China.
通讯作者:
推荐引用方式(GB/T 7714):
Yuxi Guo,Ze L I,Nan Cheng,et al.High-throughput sequencing analysis of differential microRNA expression in the process of blocking the progression of chronic atrophic gastritis to gastric cancer by Xianglian Huazhuo formula[J].Journal Of Traditional Chinese Medicine.2024,44(4):703-712.doi:10.19852/j.cnki.jtcm.20240617.002.
APA:
Yuxi Guo,Ze L I,Nan Cheng,Xuemei Jia,Jie Wang...&Qian Yang.(2024).High-throughput sequencing analysis of differential microRNA expression in the process of blocking the progression of chronic atrophic gastritis to gastric cancer by Xianglian Huazhuo formula.Journal Of Traditional Chinese Medicine,44,(4)
MLA:
Yuxi Guo,et al."High-throughput sequencing analysis of differential microRNA expression in the process of blocking the progression of chronic atrophic gastritis to gastric cancer by Xianglian Huazhuo formula".Journal Of Traditional Chinese Medicine 44..4(2024):703-712